294 related articles for article (PubMed ID: 26228486)
61. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
62. Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
Coors EA; Schuler G; Von Den Driesch P
Eur J Dermatol; 2006; 16(4):391-3. PubMed ID: 16935796
[TBL] [Abstract][Full Text] [Related]
63. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.
Suchin KR; Junkins-Hopkins JM; Rook AH
Arch Dermatol; 2002 Sep; 138(9):1137-9. PubMed ID: 12224972
[No Abstract] [Full Text] [Related]
64. The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma.
Herrick C; Heald P
Dermatol Clin; 1997 Jan; 15(1):149-57. PubMed ID: 9001868
[TBL] [Abstract][Full Text] [Related]
65. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Rook AH; Wood GS; Duvic M; Vonderheid EC; Tobia A; Cabana B
J Am Acad Dermatol; 2010 Dec; 63(6):984-90. PubMed ID: 20889234
[TBL] [Abstract][Full Text] [Related]
66. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
67. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
68. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
69. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Heald PW; Glusac EJ
J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):283-5. PubMed ID: 10642687
[TBL] [Abstract][Full Text] [Related]
70. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.
Ferenczi K; Ohtola J; Aubert P; Kessler M; Sugiyama H; Somani AK; Gilliam AC; Chen JZ; Yeh I; Matsuyama S; McCormick TS; Cooper KD
Br J Dermatol; 2010 Sep; 163(3):564-71. PubMed ID: 20408834
[TBL] [Abstract][Full Text] [Related]
71. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
72. Subcutaneous panniculitis-like T-cell lymphoma αβ: complete sustained remission with corticosteroids and methotrexate.
Briki H; Bouaziz JD; Molinier-Frenkel V; Delfau-Larue MH; Ortonne N; Bagot M
Br J Dermatol; 2010 Nov; 163(5):1136-8. PubMed ID: 20649797
[No Abstract] [Full Text] [Related]
73. Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
Bassiri-Tehrani S; BA BA; Cohen DE
Int J Dermatol; 2002 Feb; 41(2):104-6. PubMed ID: 11982647
[No Abstract] [Full Text] [Related]
74. Detection of clonal T cells in cutaneous T cell lymphoma by polymerase chain reaction: comparison of mutation detection enhancement-polyacrylamide gel electrophoresis, temperature gradient gel electrophoresis and fragment analysis of sequencing gels.
Scheller U; Muche JM; Sterry W; Lukowsky A
Electrophoresis; 1998 May; 19(5):653-8. PubMed ID: 9629892
[TBL] [Abstract][Full Text] [Related]
75. A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
Block MS; Nevala WK; Pang YP; Allred JB; Strand C; Markovic SN
Melanoma Res; 2019 Aug; 29(4):420-427. PubMed ID: 30520800
[TBL] [Abstract][Full Text] [Related]
76. Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Johnson WT; Leeman-Neill RJ; Patel P; Ho J; Grandinetti LM; Jedrych J; Craig FE
Am J Dermatopathol; 2016 Nov; 38(11):832-837. PubMed ID: 27322928
[TBL] [Abstract][Full Text] [Related]
77. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.
Nicolay JP; Melchers S; Albrecht JD; Assaf C; Dippel E; Stadler R; Wehkamp U; Wobser M; Zhao J; Burghaus I; Schneider S; Gülow K; Goerdt S; Schürch CM; Utikal JS; Krammer PH
Blood; 2023 Aug; 142(9):794-805. PubMed ID: 37217183
[TBL] [Abstract][Full Text] [Related]
78. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
[TBL] [Abstract][Full Text] [Related]
79. Resiquimod, a topical drug for viral skin lesions and skin cancer.
Meyer T; Surber C; French LE; Stockfleth E
Expert Opin Investig Drugs; 2013 Jan; 22(1):149-59. PubMed ID: 23205468
[TBL] [Abstract][Full Text] [Related]
80. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
de Masson A; Darbord D; Dobos G; Boisson M; Roelens M; Ram-Wolff C; Cassius C; Le Buanec H; de la Grange P; Jouenne F; Louveau B; Sadoux A; Bouaziz JD; Marie-Cardine A; Bagot M; Moins-Teisserenc H; Mourah S; Battistella M
Blood; 2022 Mar; 139(12):1820-1832. PubMed ID: 34905599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
